Yong‐Ching Yang - Concepedia

Author

Yong‐Ching Yang

Also Known As

Yong-Ching Yang, Yong-ching Yang, Yong‐Ching Yang

Publications

408

Citations

H-Index

Concepts

All Affiliations

Yong‐Ching Yang is an author at Forma Therapeutics (United States) specializing in medicine, pharmacology, and drug discovery.

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	240
2	Cell Biology	3	3	96
3	Health Sciences	2	2	90
4	Natural Sciences	1	1	72
5	Biochemistry	1	1	72

Yong‐Ching Yang

Publications

408

Citations

H-Index

Page 1

	Year	Citations
BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90 Karen Lundgren, Hong Zhang, John Brekken, Molecular Cancer Therapeutics	2009	168
BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance Hong Zhang, Laura Neely, Karen Lundgren, International Journal of Cancer PathologyMultidrug ResistancePharmacotherapyTumor BiologyDrug Resistance	2009	72
Orally Active Purine-Based Inhibitors of the Heat Shock Protein 90 Marco A. Biamonte, Jiandong Shi, Kevin Hong, Journal of Medicinal Chemistry Medicinal ChemistryPharmaceutical ScienceBiochemistryHsp90 InhibitorsMedicine	2005	72
Identification of new biomarkers for clinical trials of Hsp90 inhibitors Hong Zhang, Daun Chung, Yong‐Ching Yang, Molecular Cancer Therapeutics ImmunologyPathologyNew BiomarkersPharmacotherapyBiomarker (Medicine)	2006	61
Dimeric ansamycins—A new class of antitumor Hsp90 modulators with prolonged inhibitory activity Hong Zhang, Yong‐Ching Yang, Lin Zhang, International Journal of Cancer Drug TargetApoptosisCell DeathPharmacotherapyTumor Biology	2006	18
Heparin-steroid conjugates lacking glucocorticoid or mineralocorticoid activities inhibit the proliferation of vascular endothelial cells Alaine J. Derbyshire, Yong‐Ching Yang, Shuzhen Li, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research Endothelial Cell PathobiologyInflammationAngiogenesisHeparin-steroid ConjugatesMedicine	1996	17

Page 1